Cécile Haumaitre

Dr. Cécile Haumaitre

INSERM UMR1149, ERL CNRS 8252, Université Paris Diderot, F-75018 Paris, France
orcid

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 February 2013 in Nature
Verified
Journal Article
Closed access
JKJan-Wilhelm Kornfeld
Jan-Wilhelm Kornfeld
CBCatherina Baitzel
Catherina Baitzel
AKA. Christine Könner
A. Christine Könner
HNHayley T. Nicholls
Hayley T. Nicholls
MVMerly C. Vogt
Merly C. Vogt
JBJens C. Brüning
Jens C. Brüning

24 January 2005 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
CHCécile Haumaitre
Cécile Haumaitre
EBE. Barbacci
E. Barbacci
MJM. Jenny
M. Jenny
MOM. O. Ott
M. O. Ott
GGG. Gradwohl
G. Gradwohl
SCS. Cereghini
S. Cereghini
Heterozygous mutations in the human POU-homeobox TCF2 ( vHNF1, HNF1 β) gene are associated with maturity-onset diabetes of the young, type 5, and abnormal urogenital tract development. Recently, pancreas atrophies have been reported in several maturity-onset diabetes of the young type 5 patients, suggesting that TCF2 is required not only for adult pancreas function but also for its normal development. Tcf2 -deficient mice die before gastrulation because of defective visceral endoderm formation. To investigate the role of this factor in pancreas development, we rescued this early lethality by tetraploid aggregation. We show that TCF2 has an essential function in the first steps of pancreas development, correlated with its expression domain that demarcates the entire pancreatic buds from the earliest stages. Lack of TCF2 results in pancreas agenesis by embryonic day 13.5. At earlier stages, only a dorsal bud rudiment forms transiently and expresses the transcription factors Ipf1 and Hlxb9 but lacks the key transcription factor involved in the acquisition of a pancreatic fate, Ptf1a , as well as all endocrine precursor cells. Regional specification of the gut also is perturbed in Tcf2 -/- embryos as manifested by ectopic expression of Shh and lack of Ihh and Ipf1 in the posterior stomach and duodenum. Our results highlight the requirement of Tcf2 for ensuring both accurate expression of key regulator molecules in the stomach–duodenal epithelium and proper acquisition of the pancreatic fate. This study provides further insights into early molecular events controlling pancreas development and may contribute to the development of cell-replacement strategies for diabetes.

1 October 2008 in Molecular and Cellular Biology
Verified
Journal Article
Closed access
CHCécile Haumaitre
Cécile Haumaitre
OLOlivia Lenoir
Olivia Lenoir
RSRaphaël Scharfmann
Raphaël Scharfmann
During pancreas development, transcription factors play critical roles in exocrine and endocrine differentiation. Transcriptional regulation in eukaryotes occurs within chromatin and is influenced by posttranslational histone modifications (e.g., acetylation) involving histone deacetylases (HDACs). Here, we show that HDAC expression and activity are developmentally regulated in the embryonic rat pancreas. We discovered that pancreatic treatment with different HDAC inhibitors (HDACi) modified the timing and determination of pancreatic cell fate. HDACi modified the exocrine lineage via abolition and enhancement of acinar and ductal differentiation, respectively. Importantly, HDACi treatment promoted the NGN3 proendocrine lineage, leading to an increased pool of endocrine progenitors and modified endocrine subtype lineage choices. Interestingly, treatments with trichostatin A and sodium butyrate, two inhibitors of both class I and class II HDACs, enhanced the pool of beta cells. These results highlight the roles of HDACs at key points in exocrine and endocrine differentiation. They show the powerful use of HDACi to switch pancreatic cell determination and amplify specific cellular subtypes, with potential applications in cell replacement therapies in diabetes.

2 October 2005 in Nature Neuroscience
Verified
Journal Article
Closed access
PDF file
GKGéraldine Kerjan
Géraldine Kerjan
JDJackie Dolan
Jackie Dolan
CHCécile Haumaitre
Cécile Haumaitre
SSSylvie Schneider-Maunoury
Sylvie Schneider-Maunoury
HFHajime Fujisawa
Hajime Fujisawa
ACAlain Chedotal
Alain Chedotal

1 March 2015 in Development
Verified
Journal Article
Closed access
PDF file
MVMatias G. De Vas
Matias G. De Vas
JKJanel L. Kopp
Janel L. Kopp
CHClaire Heliot
Claire Heliot
MSMaike Sander
Maike Sander
SCSilvia Cereghini
Silvia Cereghini
CHCécile Haumaitre
Cécile Haumaitre
Heterozygous mutations in the human HNF1B gene are associated with maturity-onset diabetes of the young type 5 (MODY5) and pancreas hypoplasia. In mouse, Hnf1b heterozygous mutants do not exhibit any phenotype, whereas the homozygous deletion in the entire epiblast leads to pancreas agenesis associated with abnormal gut regionalization. Here, we examine the specific role of Hnf1b during pancreas development, using constitutive and inducible conditional inactivation approaches at key developmental stages. Hnf1b early deletion leads to a reduced pool of pancreatic multipotent progenitor cells (MPCs) due to decreased proliferation and increased apoptosis. Lack of Hnf1b either during the first or the secondary transitions is associated with cystic ducts. Ductal cells exhibit aberrant polarity and decreased expression of several cystic disease genes, some of which we identified as novel Hnf1b targets. Notably, we show that Glis3, a transcription factor involved in duct morphogenesis and endocrine cell development, is downstream Hnf1b. In addition, a loss and abnormal differentiation of acinar cells are observed. Strikingly, inactivation of Hnf1b at different time points results in the absence of Ngn3+ endocrine precursors throughout embryogenesis. We further show that Hnf1b occupies novel Ngn3 putative regulatory sequences in vivo. Thus, Hnf1b plays a crucial role in the regulatory networks that control pancreatic MPC expansion, acinar cell identity, duct morphogenesis and generation of endocrine precursors. Our results uncover an unappreciated requirement of Hnf1b in endocrine cell specification and suggest a mechanistic explanation of diabetes onset in individuals with MODY5.

17 October 2011 in Diabetes
Verified
Journal Article
Open access
PDF file
OLOlivia Lenoir
Olivia Lenoir
KFKathleen Flosseau
Kathleen Flosseau
FMFeng Xia Ma
Feng Xia Ma
BBBertrand Blondeau
Bertrand Blondeau
AMAntonello Mai
Antonello Mai
RSRaphaël Scharfmann
Raphaël Scharfmann
OBJECTIVE Class IIa histone deacetylases (HDACs) belong to a large family of enzymes involved in protein deacetylation and play a role in regulating gene expression and cell differentiation. Previously, we showed that HDAC inhibitors modify the timing and determination of pancreatic cell fate. The aim of this study was to determine the role of class IIa HDACs in pancreas development. RESEARCH DESIGN AND METHODS We took a genetic approach and analyzed the pancreatic phenotype of mice lacking HDAC4, -5, and -9. We also developed a novel method of lentiviral infection of pancreatic explants and performed gain-of-function experiments. RESULTS We show that class IIa HDAC4, -5, and -9 have an unexpected restricted expression in the endocrine β- and δ-cells of the pancreas. Analyses of the pancreas of class IIa HDAC mutant mice revealed an increased pool of insulin-producing β-cells in Hdac5−/− and Hdac9−/− mice and an increased pool of somatostatin-producing δ-cells in Hdac4−/− and Hdac5−/− mice. Conversely, HDAC4 and HDAC5 overexpression showed a decreased pool of insulin-producing β-cells and somatostatin-producing δ-cells. Finally, treatment of pancreatic explants with the selective class IIa HDAC inhibitor MC1568 enhances expression of Pax4, a key factor required for proper β-and δ-cell differentiation and amplifies endocrine β- and δ-cells. CONCLUSIONS We conclude that HDAC4, -5, and -9 are key regulators to control the pancreatic β/δ-cell lineage. These results highlight the epigenetic mechanisms underlying the regulation of endocrine cell development and suggest new strategies for β-cell differentiation-based therapies.